Shares of Immunome Inc. (IMNM) plunged 5.08% in Friday's trading session following the release of the company's disappointing Full Year 2024 financial results. The biotechnology firm reported a significant widening of its net loss and missed analyst expectations on both revenue and earnings.

According to the earnings report, Immunome's net loss for the fiscal year 2024 expanded to $293.0 million, representing a substantial 174% increase from the previous year. The company reported a loss per share of $5.00, which was 14% worse than analysts had predicted. Additionally, revenue fell short of expectations by 3.9%, although specific figures were not provided in the available information.

This negative financial performance has clearly rattled investors, leading to the sharp decline in Immunome's stock price. The plummet comes on top of an already challenging week for the company, as its shares were reported to be down 3.0% over the past seven days prior to this latest drop. The combination of widening losses, missed estimates, and the overall market sentiment towards biotechnology stocks may have contributed to the significant sell-off observed on Friday.